Raloxifene induces nucleolar translocation of the estrogen receptor

Molecular and Cellular Endocrinology

Volumn 319, Issue 1-2, 2010, Pages 14-22

  Gushima, Mika ^a   Kawate, Hisaya ^a   Ohnaka, Keizo ^a   Nomura, Masatoshi ^a   Takayanagi, Ryoichi ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Estrogen receptor; GFP; Nucleolus; SERM

Indexed keywords

ESTROGEN RECEPTOR ALPHA; RALOXIFENE;

ANIMAL CELL; ARTICLE; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; ENZYME INHIBITION; FLUORESCENCE RECOVERY AFTER PHOTOBLEACHING; GENE ACTIVATION; GENE MUTATION; GENE TRANSLOCATION; HORMONE INHIBITION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; MOLECULAR DYNAMICS; MUTATIONAL ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; SITE DIRECTED MUTAGENESIS;

ANIMALS; CELL NUCLEOLUS; CELLS, CULTURED; ESTROGEN RECEPTOR ALPHA; FLUORESCENCE RECOVERY AFTER PHOTOBLEACHING; FLUORESCENT ANTIBODY TECHNIQUE; GREEN FLUORESCENT PROTEINS; HUMANS; MICROSCOPY, CONFOCAL; PROTEIN STRUCTURE, SECONDARY; PROTEIN TRANSPORT; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 77249114655     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2010.01.006     Document Type: Article

References (40)

1. Andersen J.S., Lam Y.W., Leung A.K., Ong S.E., Lyon C.E., Lamond A.I., and Mann M. Nucleolar proteome dynamics. Nature 433 (2005) 77-83
2. Aranda A., and Pascual A. Nuclear hormone receptors and gene expression. Physiol. Rev. 81 (2001) 1269-1304
3. Barrett-Connor E., Mosca L., Collins P., Geiger M.J., Grady D., Kornitzer M., McNabb M.A., Wenger N.K., and Raloxifene Use for The Heart (RUTH) Trial Investigators. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N. Engl. J. Med. 355 (2006) 125-137
4. Black L.J., Sato M., Rowley E.R., Magee D.E., Bekele A., Williams D.C., Cullinan G.J., Bendele R., Kauffman R.F., Bensch W.R., Frolik C.A., Termine J.D., and Bryant H.U. Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J. Clin. Invest. 93 (1994) 63-69
5. Boisvert F.M., van Koningsbruggen S., Navascués J., and Lamond A.I. The multifunctional nucleolus. Nat. Rev. Mol. Cell. Biol. 8 (2007) 574-585
6. Brzozowski A.M., Pike A.C., Dauter Z., Hubbard R.E., Bonn T., Engström O., Ohman L., Greene G.L., Gustafsson J.A., and Carlquist M. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389 (1997) 753-758
7. Cummings S.R., Eckert S., Krueger K.A., Grady D., Powles T.J., Cauley J.A., Norton L., Nickelsen T., Bjarnason N.H., Morrow M., Lippman M.E., Black D., Glusman J.E., Costa A., and Jordan V.C. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple outcomes of raloxifene evaluation. JAMA 281 (1999) 2189-2197
8. Cuzick J., and Baum M. Tamoxifen and contralateral breast cancer. Lancet 326 (1985) 282
9. Delmas P.D., Ensrud K.E., Adachi J.D., Harper K.D., Sarkar S., Gennari C., Reginster J.Y., Pols H.A., Recker R.R., Harris S.T., Wu W., Genant H.K., Black D.M., Eastell R., and Mulitple Outcomes of Raloxifene Evaluation Investigators. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J. Clin. Endocrinol. Metab. 87 (2002) 3609-3617
10. Ettinger B., Black D.M., Mitlak B.H., Knickerbocker R.K., Nickelsen T., Genant H.K., Christiansen C., Delmas P.D., Zanchetta J.R., Stakkestad J., Glüer C.C., Krueger K., Cohen F.J., Eckert S., Ensrud K.E., Avioli L.V., Lips P., and Cummings S.R. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282 (1999) 637-645
11. Fisher B., Costantino J., Redmond C., Poisson R., Bowman D., Couture J., Dimitrov N.V., Wolmark N., Wickerham D.L., Fisher E.R., Margolese R., Robidoux A., Shibata H., Terz J., Paterson A.H.G., Feldman M.I., Farrar W., Evans J., Lickley H.L., and Ketner M. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N. Engl. J. Med. 320 (1989) 479-484
12. Fisher B., Costantino J.P., Redmond C.K., Fisher E.R., Wickerham D.L., and Cronin W.M. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J. Natl. Cancer Inst. 86 (1994) 527-537
13. Grodstein F., Stampfer M.J., Manson J.E., Colditz G.A., Willett W.C., Rosner B., Speizer F.E., and Hennekens C.H. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N. Engl. J. Med. 335 (1996) 453-461
14. Htun H., Holth L.T., Walker D., Davie J.R., and Hager G.L. Direct visualization of the human estrogen receptor alpha reveals a role for ligand in the nuclear distribution of the receptor. Mol. Biol. Cell. 10 (1999) 471-486
15. Kawate H., Wu Y., Ohnaka K., Tao R.H., Nakamura K., Okabe T., Yanase T., Nawata H., and Takayanagi R. Impaired nuclear translocation, nuclear matrix targeting, and intranuclear mobility of mutant androgen receptors carrying amino acid substitutions in the deoxyribonucleic acid-binding domain derived from androgen insensitivity syndrome patients. J. Clin. Endocrinol. Metab. 90 (2005) 6162-6169
16. Kessels M.M., Qualmann B., Thole H.H., and Sierralta W.D. Subcellular localization of estradiol receptor in MCF7 cells studied with nanogold-labelled antibody fragments. Eur. J. Histochem. 42 (1998) 259-270
17. Kinyamu H.K., and Archer T.K. Modifying chromatin to permit steroid hormone receptor-dependent transcription. Biochim. Biophys. Acta 1677 (2004) 30-45
18. Lonard D.M., Tsai S.Y., and O'Malley B.W. Selective estrogen receptor modulators 4-hydroxytamoxifen and raloxifene impact the stability and function of SRC-1 and SRC-3 coactivator proteins. Mol. Cell. Biol. 24 (2004) 14-24
19. Love R.R., Mazess R.B., Barden H.S., Epstein S., Newcomb P.A., Jordan V.C., Carbone P.P., and DeMets D.L. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N. Engl. J. Med. 326 (1992) 852-856
20. Lupien M., Jeyakumar M., Hébert E., Hilmi K., Cotnoir-White D., Loch C., Auger A., Dayan G., Pinard G.A., Wurtz J.M., Moras D., Katzenellenbogen J., and Mader S. Raloxifene and ICI 182,780 increase estrogen receptor-α association with a nuclear compartment via overlapping sets of hydrophobic amino acids in activation function 2 helix 12. Mol. Endocrinol. 21 (2007) 797-816
21. Moras D., and Gronemeyer H. The nuclear receptor ligand-binding domain: structure and function. Curr. Opin. Cell Biol. 10 (1998) 384-391
22. Olson M.O., Hingorani K., and Szebeni A. Conventional and nonconventional roles of the nucleolus. Int. Rev. Cytol. 219 (2002) 199-266
23. Phair R.D., and Misteli T. High mobility of proteins in the mammalian cell nucleus. Nature 404 (2000) 604-609
24. Rossouw J.E., Anderson G.L., Prentice R.L., LaCroix A.Z., Kooperberg C., Stefanick M.L., Jackson R.D., Beresford S.A., Howard B.V., Johnson K.C., Kotchen J.M., Ockene J., and Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288 (2002) 321-333
25. Saitoh M., Takayanagi R., Goto K., Fukamizu A., Tomura A., Yanase T., and Nawata H. The presence of both the amino- and carboxyl-terminal domains in the AR is essential for the completion of a transcriptionally active form with coactivators and intranuclear compartmentalization common to the steroid hormone receptors: a three-dimensional imaging study. Mol. Endocrinol. 16 (2002) 694-706
26. Shang Y., and Brown M. Molecular determinants for the tissue specificity of SERMs. Science 295 (2002) 2465-2468
27. Shiau A.K., Barstad D., Loria P.M., Cheng L., Kushner P.J., Agard D.A., and Greene G.L. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 95 (1998) 927-937
28. Smith C.L., Nawaz Z., and O'Malley B.W. Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. Mol. Endocrinol. 11 (1997) 657-666
29. Solakidi S., Psarra A.M., and Sekeris C.E. Differential subcellular distribution of estrogen receptor isoforms: localization of ERalpha in the nucleoli and ERbeta in the mitochondria of human osteosarcoma SaOS-2 and hepatocarcinoma HepG2 cell lines. Biochim. Biophys. Acta 1745 (2005) 382-392
30. Solakidi S., Psarra A.M., and Sekeris C.E. Differential distribution of glucocorticoid and estrogen receptor isoforms: localization of GRbeta and ERalpha in nucleoli and GRalpha and ERbeta in the mitochondria of human osteosarcoma SaOS-2 and hepatocarcinoma HepG2 cell lines. J. Musculoskelet. Neuronal. Interact. 7 (2007) 240-245
31. Stenoien D.L., Mancini M.G., Patel K., Allegretto E.A., Smith C.L., and Mancini M.A. Subnuclear trafficking of estrogen receptor-α and steroid receptor coactivator-1. Mol. Endocrinol. 14 (2000) 518-534
32. Stenoien D.L., Patel K., Mancini M.G., Dutertre M., Smith C.L., O'Malley B.W., and Mancini M.A. FRAP reveals that mobility of oestrogen receptor-α is ligand- and proteasome-dependent. Nat. Cell Biol. 3 (2001) 15-23
33. Torgerson D.J., and Bell-Syer S.E. Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials. JAMA 285 (2001) 2891-2897
34. Tsai M.J., and O'Malley B.W. Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu. Rev. Biochem. 63 (1994) 451-486
35. Vázquez-Nin G.H., Echeverría O.M., Fakan S., Traish A.M., Wotiz H.H., and Martin T.E. Immunoelectron microscopic localization of estrogen receptor on pre-mRNA containing constituents of rat uterine cell nuclei. Exp. Cell Res. 192 (1991) 396-404
36. Vogel V.G., Costantino J.P., Wickerham D.L., Cronin W.M., Cecchini R.S., Atkins J.N., Bevers T.B., Fehrenbacher L., Pajon Jr. E.R., Wade III J.L., Robidoux A., Margolese R.G., James J., Lippman S.M., Runowicz C.D., Ganz P.A., Reis S.E., McCaskill-Stevens W., Ford L.G., Jordan V.C., Wolmark N., and National Surgical Adjuvant Breast and Bowel Project (NSABP). Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 295 (2006) 2727-2741
37. Wijayaratne A.L., and McDonnell D.P. The human estrogen receptor-alpha is a ubiquitinated protein whose stability is affected differentially by agonists, antagonists, and selective estrogen receptor modulators. J. Biol. Chem. 276 (2001) 35684-35692
38. Wu Y.L., Yang X., Ren Z., McDonnell D.P., Norris J.D., Willson T.M., and Greene G.L. Structural basis for an unexpected mode of SERM-mediated ER antagonism. Mol. Cell 18 (2005) 413-424
39. Wu Y., Kawate H., Ohnaka K., Nawata H., and Takayanagi R. Nuclear compartmentalization of N-CoR and its interactions with steroid receptors. Mol. Cell. Biol. 26 (2006) 6633-6655
40. Zhang X., Jeyakumar M., Petukhov S., and Bagchi M.K. A nuclear receptor corepressor modulates transcriptional activity of antagonist-occupied steroid hormone receptor. Mol. Endocrinol. 12 (1998) 513-524